Bronchiectasis: Why symptom control isn't enough anymore

Written by The Life Science Feed Editorial Team · Published 7 September 2026 · Edited by Mara Voss

Bronchiectasis, a chronic respiratory condition characterised by permanent dilation of the bronchi and recurrent infections, presents a significant management challenge. The cycle of inflammation, infection, and airway damage perpetuates disease progression, leading to a substantial burden on patients and healthcare systems. Current therapeutic strategies primarily focus on symptom control and reducing exacerbations, but the field is actively exploring interventions that could fundamentally alter the disease course.

KEY TAKEAWAYS

- The Pivot: Emerging strategies aim to target neutrophil-driven inflammation, moving beyond current symptomatic management to potential disease modification.
- The Data: While specific trial data is not yet available for novel disease-modifying agents, the mechanistic understanding points to neutrophil elastase inhibition as a key pathway.
- The Action: Clinicians should continue to adhere to established guidelines for airway clearance and infection control, while remaining aware of the evolving therapeutic landscape for bronchiectasis.

Bronchiectasis is a heterogeneous disorder marked by chronic cough, sputum production, and recurrent respiratory infections. The underlying pathology involves a vicious cycle where impaired mucociliary clearance leads to bacterial colonisation, which in turn triggers a robust inflammatory response. This inflammation, particularly driven by neutrophils, releases proteases that damage the bronchial walls, leading to irreversible dilation and further impairment of clearance mechanisms. This cycle is central to the progressive nature of the disease, and breaking it represents a critical unmet need in patient care.

Patients with bronchiectasis often experience a decline in lung function over time, alongside a reduced quality of life. The frequency and severity of exacerbations are key determinants of prognosis, driving hospitalisations and accelerating lung damage. Existing management strategies, while vital, largely address the consequences rather than the root causes of this destructive cycle. These include regular airway clearance techniques, long-term antibiotic therapy for chronic infection, and prompt treatment of exacerbations. But these approaches do not halt the underlying structural damage.

The Inflammatory Cascade in Bronchiectasis

The pathogenesis of bronchiectasis is complex, but a common thread across various etiologies (such as post-infectious, cystic fibrosis related, or idiopathic) is the prominent role of neutrophilic inflammation. Neutrophils are recruited to the airways in response to bacterial colonisation and infection. Once activated, these immune cells release a potent cocktail of inflammatory mediators, including neutrophil elastase (NE), matrix metalloproteinases (MMPs), and reactive

oxygen species. These enzymes are highly destructive, degrading elastin and collagen in the bronchial wall, leading to the characteristic airway dilation. The persistent presence of these mediators creates a self-perpetuating inflammatory environment.

Neutrophil elastase, in particular, is a key player in this destructive process. It not only directly damages airway tissue but also impairs mucociliary function by degrading components of mucus and ciliary proteins. NE can activate other inflammatory pathways, amplifying the overall immune response and contributing to mucus hypersecretion. The sustained activity of NE in the airways of patients with bronchiectasis makes it an attractive target for therapeutic intervention. Inhibiting NE could theoretically reduce airway damage, improve mucociliary clearance, and dampen the overall inflammatory burden, thereby potentially modifying the disease course.

Current Standard of Care and Its Limitations

The current management of bronchiectasis focuses on three main pillars: improving airway clearance, controlling infection, and managing inflammation. Airway clearance techniques (ACTs), such as chest physiotherapy, oscillatory positive expiratory pressure (PEP) devices, and autogenic drainage, are fundamental. These methods aim to mobilise and remove sputum, reducing bacterial load and improving ventilation. Regular adherence to ACTs is important for patients' long-term lung health, but compliance can be challenging, and their impact on long-term structural changes is limited.

Infection control often involves long-term suppressive antibiotic therapy, particularly in patients with frequent exacerbations or chronic colonisation by pathogens like Pseudomonas aeruginosa. Macrolides, such as azithromycin, are frequently used for their anti-inflammatory and immunomodulatory effects, in addition to their antimicrobial properties. Inhaled antibiotics, like tobramycin or colistin, are also employed to deliver high concentrations of medication directly to the airways, minimising systemic side effects. While these strategies reduce exacerbations and improve quality of life, they do not prevent the progressive structural damage to the bronchi. The emergence of antibiotic resistance is also a significant concern with long-term use.

Anti-inflammatory treatments, beyond macrolides, are less well-defined. Systemic corticosteroids are generally avoided due to their significant side effect profile and limited evidence of long-term benefit in non-cystic fibrosis bronchiectasis. Inhaled corticosteroids are sometimes used, particularly in patients with co-existing asthma or COPD, but their role in isolated bronchiectasis is not clearly established. The lack of specific anti-inflammatory agents that can safely and effectively target the chronic neutrophilic inflammation without broad immunosuppression highlights a major therapeutic gap. For a deeper understanding of general respiratory conditions, the Oxford Handbook of Respiratory Medicine provides a concise reference.

Targeting Neutrophil Elastase: A Path to Disease Modification

The recognition of neutrophil elastase as a central mediator of airway damage has spurred interest in developing specific NE inhibitors. These agents are designed to neutralise the destructive activity of NE, thereby protecting the bronchial epithelium and extracellular matrix from degradation. By disarming this key inflammatory enzyme, the hope is to interrupt the vicious cycle of inflammation and damage, potentially slowing or even halting disease progression. This represents a significant shift from purely symptomatic management to a strategy focused on disease modification.

Several NE inhibitors have been investigated in various inflammatory lung diseases, including cystic fibrosis and alpha-1 antitrypsin deficiency. The rationale for their use in bronchiectasis is compelling, given the shared pathological features

of excessive neutrophilic inflammation and protease-mediated tissue destruction. These compounds typically work by binding irreversibly to NE, rendering it inactive. The challenge lies in delivering these inhibitors effectively to the site of inflammation in the airways and ensuring sustained inhibition without off-target effects.

The development of inhaled formulations of NE inhibitors is particularly attractive, as it allows for high local concentrations in the lung while minimising systemic exposure. This approach could offer a more favourable safety profile compared to systemic anti-inflammatory agents. The goal is to reduce the burden of NE activity in the airways, which could translate into reduced sputum purulence, improved lung function, and a decrease in exacerbation frequency. Such an intervention would represent a substantial advance over current therapies, which primarily manage symptoms and complications. The concept of targeting specific epithelial dysfunction is also gaining traction in broader airway disease management, as discussed in our coverage on epithelial dysfunction as a unified target.

Challenges and Future Directions

While the mechanistic rationale for NE inhibition is strong, translating this into a clinically meaningful benefit for patients with bronchiectasis presents several challenges. The heterogeneity of the disease, with various underlying etiologies and differing inflammatory phenotypes, means that a one-size-fits-all approach may not be optimal. Identifying specific patient subgroups most likely to respond to NE inhibition will be vital for successful therapeutic development. Biomarkers of neutrophilic inflammation, such as sputum NE activity or myeloperoxidase levels, could play a vital role in patient selection and monitoring treatment response.

The long-term safety of NE inhibitors also needs careful evaluation. While inhaled delivery aims to minimise systemic effects, any potential impact on host defence mechanisms, particularly against bacterial or viral infections, must be thoroughly assessed. Neutrophils play a critical role in innate immunity, and broad inhibition of their enzymes could theoretically compromise the body's ability to clear pathogens. Balancing the anti-inflammatory benefits with the need to maintain effective host defence is a delicate act.

Another consideration is the timing of intervention. Could NE inhibitors be most effective in earlier stages of the disease, before extensive structural damage has occurred? Or could they still offer significant benefit in patients with established bronchiectasis by preventing further progression? These questions will need to be addressed in future clinical studies.

The field is also exploring other anti-inflammatory targets beyond NE, including inhibitors of other proteases, cytokines, or signalling pathways involved in neutrophilic inflammation. The ultimate goal is to move towards a precision medicine approach, tailoring therapies to the individual patient's inflammatory profile and disease drivers.

The development of novel therapies for bronchiectasis is a slow but steady process. The journey from understanding the pathophysiology to developing effective disease-modifying agents requires rigorous clinical investigation. While no specific trial data for novel NE inhibitors in bronchiectasis has been presented, the ongoing research in this area offers a glimmer of hope for patients who currently rely on therapies that only manage symptoms. The focus on disarming the neutrophil represents a strategic shift, aiming to break the destructive cycle at its core. This approach, if successful, could fundamentally change the prognosis for many individuals living with this chronic and debilitating lung condition. For clinicians managing complex respiratory cases, staying updated on these developments is essential, and resources like the latest updates in ILD diagnosis and management can provide broader context on pulmonary care advancements.

CLINICAL IMPLICATIONS

> The shift towards targeting neutrophil-driven inflammation in bronchiectasis represents a significant conceptual leap. For too long, management has been a reactive exercise in damage control, focusing on clearing airways and suppressing infections. A therapy that could genuinely modify the disease course by interrupting the destructive inflammatory cycle would be transformative.
> Clinicians should recognise that while current guidelines remain the bedrock of care, the therapeutic market is not static. The potential for agents like neutrophil elastase inhibitors to move beyond symptom management into true disease modification means we may soon have tools that alter the natural history of bronchiectasis, not just its manifestations. This would necessitate a re-evaluation of when and how we intervene, potentially shifting towards earlier, more aggressive anti-inflammatory strategies.
> The industry's focus on these specific inflammatory pathways is a welcome development. But the challenge lies in demonstrating not just biochemical efficacy, but tangible clinical benefits in a heterogeneous patient population. Any new agent will need to show a clear advantage over existing, albeit imperfect, therapies, particularly regarding long-term safety and impact on lung function decline and exacerbation rates. The bar for adoption will be high, and rightly so.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. O'Donnell AE. Bronchiectasis - A Clinical Review. N Engl J Med. 2022;387(6):533-545. doi:10.1056/NEJMra2202819
2. 2. Doumat G, Aksamit TR, Kanj AN. Bronchiectasis: A clinical review of inflammation. Respir Med. 2025;244:108179. doi:10.1016/j.rmed.2025.108179
3. 3. Elborn JS, Blasi F, Haworth CS, et al. Bronchiectasis and inhaled tobramycin: A literature review. Respir Med. 2022;192:106728. doi:10.1016/j.rmed.2021.106728
4. 4. Conceição M, Shteinberg M, Goeminne P, Altenburg J, Chalmers JD. Eradication treatment for Pseudomonas aeruginosa infection in adults with bronchiectasis: a systematic review and meta-analysis. Eur Respir Rev. 2024;33(171). doi:10.1183/16000617.0178-2023
5. 5. Gudmundsson G, Juliusson G. [Bronchiectasis - a review]. Laeknabladid. 2020;106(7):352-361. doi:10.17992/lbl.2020.0708.592
6. 6. Chalmers JD, Mall MA, McShane PJ, et al. A systematic literature review of the clinical and socioeconomic burden of bronchiectasis. Eur Respir Rev. 2024;33(173). doi:10.1183/16000617.0049-2024

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED